Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
UBS
Fish and Richardson
Boehringer Ingelheim
Queensland Health
McKesson
Teva
US Army
Johnson and Johnson

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,927,624

« Back to Dashboard

Summary for Patent: 7,927,624
Title:Hydrophilic/lipophilic polymeric matrix dosage formulation
Abstract: An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.
Inventor(s): Vergnault; Guy (Loechle, FR), Grenier; Pascal (Kappelen, FR), Maggi; Lauretta (Pavia, IT), Conte; Ubaldo (Busto Arsizio, IT)
Assignee: Jagotec AG (Muttenz, CH)
Application Number:11/717,502
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Use;

Drugs Protected by US Patent 7,927,624

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-001 Jun 13, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-003 Jun 13, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT ➤ Try a Free Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,927,624

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI2000A0852Apr 14, 2000
ItalyMI2000A1963Sep 07, 2000

Non-Orange Book US Patents Family Members for Patent 7,927,624

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,303,986 Hydrophilic/lipophilic polymeric matrix dosage formulation ➤ Try a Free Trial
8,460,706 Hydrophilic/lipophilic polymeric matrix dosage formulation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,927,624

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 030557 ➤ Try a Free Trial
Austria 401867 ➤ Try a Free Trial
Australia 2005201805 ➤ Try a Free Trial
Australia 2009230759 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Express Scripts
Harvard Business School
Accenture
Teva
Julphar
Covington
US Department of Justice
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.